Drug Profile
Research programme: anti-cancer aptamers - Caris Life Sciences
Alternative Names: Aptamer C 10.36Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Caris Life Sciences
- Class Antineoplastics; Peptide aptamers
- Mechanism of Action Apoptosis stimulants; Heterogeneous nuclear ribonucleoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma